Advanced search
Publication Cover
Acta Oncologica Volume 57, 2018 - Issue 5
Journal homepage
3,342
Views
37
CrossRef citations to date
0
Altmetric
Letters to the Editor

Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a case report

Abdul Rafeh NaqashDivision of Hematology/Oncology, East Carolina University, Greenville, NC, USA; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0001-7622-720X
ORCID Icon,
Li V. YangDivision of Hematology/Oncology, East Carolina University, Greenville, NC, USA;
,
Edward J. SanderlinDivision of Hematology/Oncology, East Carolina University, Greenville, NC, USA;
,
Druid C. AtwellDivision of Hematology/Oncology, East Carolina University, Greenville, NC, USA;
&
Paul R. WalkerThoracic Oncology, East Carolina University, Greenville, NC, USA
Pages 705-708 | Published online: 24 Nov 2017

References

  • Rafei H, El-Bahesh E, Finianos A, et al. Immune-based therapies for non-small cell lung cancer. Anticancer Res. 2017;37:377–387.
  • Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139–148.
  • Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;16:448–457.
  • Bromberg J, Wang TC. Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell. 2009;15:79–80.
  • Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111:1805–1812.
  • Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188–195.
  • Naqash AR, Stroud CRG, Cherry C, et al. 4A.03 predictive utility of c-reactive protein (CRP) in advanced stage lung cancer treated with anti-programmed cell death-1 (PD-1) therapy. J Thorac Oncol. 2017;12:S1559.
  • Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. 2016;375:1767–1778.
  • Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33:1974–1982.
  • Balar AV, Weber JS. PD-1 and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunol Immunother. 2017;66:551–564.
  • Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255–265.
  • Salmaninejad A, Khoramshahi V, Azani A, et al. PD-1 and cancer: molecular mechanisms and polymorphisms. Immunogenetics. 2017 [22 Jun]; DOI:10.1007/s00251-017-1015-5
  • Nomizo T, Ozasa H, Tsuji T, et al. Clinical impact of single nucleotide polymorphism in PD-L1 on response to nivolumab for advanced non-small-cell lung cancer patients. Sci Rep. 2017; 7:45124.
  • Quirk SK, Shure AK, Agrawal DK. Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma. Transl Res. 2015;166:412–424.
  • Bamias G, Delladetsima I, Perdiki M, et al. Immunological characteristics of colitis associated with anti-CTLA-4 antibody therapy. Cancer Invest. 2017;35:443–455.
  • Stroud CRG, Cherry CR, Naqash AR, et al. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Clin Oncol. 2017;35:e21712.
  • Stroud CRG, Hegde A, Naqash AR, et al. OA03.05 tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade: overall survival analysis. J Thorac Oncol. 2017;12:S1554–S15S5.
  • Li N, Grivennikov Sergei I, Karin M. The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment. Cancer Cell. 2011;19:429–431.
  • Tanaka R, Okiyama N, Okune M, et al. Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-α is a biomarker of nivolumab reactivity. J Dermatol Sci. 2017;86:71–73.
  • Rotz SJ, Leino D, Szabo S, et al. Severe cytokine release syndrome in a patient receiving PD-1-directed therapy. Pediatr Blood Cancer. 2017;64:e26642.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.